According to a report by BioSpace, the European Commission has granted marketing authorisation for eltrombopag (Revolade) for the oral treatment of thrombocytopenia in adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP).

The marketing authorisation states that eltrombopag is indicated in adult chronic ITP splenectomised patients who have not responded (are refractory) to other treatments, such as corticosteroids and immunoglobulins. Furthermore, it may also be considered as second-line treatment for adult non-splenectomised patients where surgery is contraindicated.